HK Stock Market Move | BeOne Medicines Ltd. (06160) rose more than 3% in morning trading; raised full-year revenue guidance three times this year; innovative pipeline about to enter a realization phase.

BeOne Medicines Ltd. (06160) rose more than 3% in morning trading. As of press time, it was up 2.86% at HK$259, with turnover of HK$451 million. On the news front, on November 5, BeOne Medicines Ltd. released its results, reporting revenue of RMB34.993 billion for the first three quarters, up 26.8% year on year; profit was RMB6.055 billion, up 431.8% year on year. Based on the strong performance in the first three quarters, BeOne Medicines Ltd. announced another upward revision to its 2026 operating performance guidance, adjusting its full-year revenue guidance from "RMB44.9 billion to RMB46.2 billion" to "between RMB46.3 billion and RMB47 billion." Notably, this is already the company's third upward revision to its full-year performance guidance this year. China Securities Co.,Ltd. said that, considering the hematology oncology field, BeiYueZe's continued volume growth + the approval of new indications for sotorclax + BTK CDAC's expected submission of a marketing application, forming multiple drivers; in the solid tumor field, core assets such as CDK4 inhibitors, B7-H4 ADC, and GPC3 bispecific antibodies are entering Phase III registrational clinical trials, with a clear medium- to long-term growth path. We believe the company's performance fundamentals continue to strengthen, and its innovative pipeline is about to enter a realization phase, maintaining our "Buy" rating.